RhumbLine Advisers’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.12M | Buy |
156,517
+26,059
| +20% | +$187K | ﹤0.01% | 2184 |
|
|
2025
Q1 | $781K | Buy |
130,458
+4,877
| +4% | +$29.2K | ﹤0.01% | 2293 |
|
|
2024
Q4 | $980K | Buy |
125,581
+660
| +0.5% | +$5.15K | ﹤0.01% | 2259 |
|
|
2024
Q3 | $1.35M | Sell |
124,921
-5,595
| -4% | -$60.4K | ﹤0.01% | 2107 |
|
|
2024
Q2 | $1.1M | Buy |
130,516
+11,383
| +10% | +$96K | ﹤0.01% | 2187 |
|
|
2024
Q1 | $801K | Buy |
119,133
+3,182
| +3% | +$21.4K | ﹤0.01% | 2379 |
|
|
2023
Q4 | $682K | Buy |
115,951
+2,117
| +2% | +$12.4K | ﹤0.01% | 2487 |
|
|
2023
Q3 | $1.11M | Buy |
113,834
+13,679
| +14% | +$133K | ﹤0.01% | 2145 |
|
|
2023
Q2 | $1.19M | Buy |
100,155
+6,694
| +7% | +$79.3K | ﹤0.01% | 2197 |
|
|
2023
Q1 | $1.01M | Buy |
93,461
+729
| +0.8% | +$7.86K | ﹤0.01% | 2114 |
|
|
2022
Q4 | $1.07M | Buy |
92,732
+3,973
| +4% | +$45.9K | ﹤0.01% | 2095 |
|
|
2022
Q3 | $1.32M | Buy |
88,759
+25,174
| +40% | +$376K | ﹤0.01% | 1991 |
|
|
2022
Q2 | $574K | Buy |
63,585
+22,673
| +55% | +$205K | ﹤0.01% | 2423 |
|
|
2022
Q1 | $306K | Buy |
40,912
+2,057
| +5% | +$15.4K | ﹤0.01% | 2641 |
|
|
2021
Q4 | $333K | Sell |
38,855
-740
| -2% | -$6.34K | ﹤0.01% | 2674 |
|
|
2021
Q3 | $333K | Buy |
39,595
+1,315
| +3% | +$11.1K | ﹤0.01% | 2724 |
|
|
2021
Q2 | $310K | Buy |
+38,280
| New | +$310K | ﹤0.01% | 2771 |
|
|
2019
Q2 | – | Sell |
-4,868
| Closed | -$85K | – | 2974 |
|
|
2019
Q1 | $85K | Buy |
+4,868
| New | +$85K | ﹤0.01% | 2881 |
|